REATA PHARMACEUTICALS INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-09-08: Study NCT04494646; Company role Collaborator; Phase Phase 2; Status Completed.
- 2006-09: Study NCT00512460; Company role Collaborator; Phase Phase 1; Status Terminated.
- 2006-04: Study NCT00508807; Company role Collaborator; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-09-08 | NCT04494646 BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) | Collaborator Lead: NYU Langone Health | Phase 2 | Completed Results posted | Covid19 | 40 | 2021-01-08 |
| 2006-09 | NCT00512460 RTA 744 Injection in Patients With Leptomeningeal Disease | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1 | Terminated | Neoplastic Meningitis; Solid Tumor; Lymphoma; Leukemia; Brain Tumor | 7 | 2010-03 |
| 2006-04 | NCT00508807 RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies | Collaborator Lead: M.D. Anderson Cancer Center | Phase 1 | Completed | Lymphoid Malignancies; Solid Tumors | 21 | 2009-12 |